ALK-positive Large B-Cell Lymphoma With Multiple Epithelial Antigen Expression and PABPC1::ALK Fusion : A Novel Molecular Alteration

Am J Surg Pathol. 2023 Aug 1;47(8):950-954. doi: 10.1097/PAS.0000000000002069. Epub 2023 Jun 19.

Abstract

Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma (LBCL) is a very rare type of LBCL with an aggressive clinical course and poor prognosis. This diagnosis can be challenging given the varied morphology (immunoblastic, plasmablastic, or anaplastic), frequent lack of B-cell antigens, and especially in cases with expression of epithelial antigens. Here, we report a case of ALK-positive LBCL with unusual expression of 4 epithelial-associated markers (AE1/AE3, CK8/18, EMA, and GATA3) and novel poly(A) binding protein cytoplasmic 1 (PABPC1) :: ALK fusion which has not been previously reported in this entity. This case also emphasizes the use of comprehensive immunophenotyping that includes multiple lineage-specific antibodies when faced with a malignancy without a clear differentiation to avoid misdiagnosis. This case only achieved partial response to combination chemotherapy, radiation, and ALK inhibitor regimens, and furthers our understanding of this uncommon lymphoma.

Publication types

  • Case Reports

MeSH terms

  • Anaplastic Lymphoma Kinase / genetics
  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / diagnosis
  • Plasma Cells / pathology
  • Receptor Protein-Tyrosine Kinases* / genetics
  • Receptor Protein-Tyrosine Kinases* / metabolism

Substances

  • Receptor Protein-Tyrosine Kinases
  • Anaplastic Lymphoma Kinase